Secukinumab
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Juvenile Psoriatic Arthritis
Conditions
Juvenile Psoriatic Arthritis
Trial Timeline
Sep 24, 2025 → Dec 1, 2032
NCT ID
NCT06751238About Secukinumab
Secukinumab is a phase 1 stage product being developed by Novartis for Juvenile Psoriatic Arthritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06751238. Target conditions include Juvenile Psoriatic Arthritis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05583604 | Pre-clinical | Active |
| NCT07243782 | Pre-clinical | Recruiting |
| NCT06751238 | Phase 1 | Recruiting |
| NCT06905288 | Pre-clinical | Recruiting |
| NCT06331312 | Phase 3 | Recruiting |
| NCT06130540 | Phase 1 | Completed |
| NCT05569174 | Phase 3 | Completed |
| NCT05232864 | Phase 3 | Terminated |
| NCT05206591 | Phase 3 | Withdrawn |
| NCT04894890 | Pre-clinical | Completed |
| NCT04717466 | Approved | Completed |
| NCT05677542 | Pre-clinical | Completed |
| NCT05513014 | Pre-clinical | Completed |
| NCT05320159 | Pre-clinical | Completed |
| NCT05650060 | Pre-clinical | Completed |
| NCT03866317 | Phase 2 | Withdrawn |
| NCT03769168 | Phase 3 | Completed |
| NCT03791060 | Phase 2 | Terminated |
| NCT03440736 | Approved | Completed |
| NCT03307447 | Approved | UNKNOWN |
Competing Products
20 competing products in Juvenile Psoriatic Arthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PLX-200 + Placebo | Polaryx Therapeutics | Phase 3 | 69 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) + placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| Adalimumab | Eisai | Phase 3 | 77 |
| Abatacept | Ono Pharmaceutical | Phase 3 | 77 |
| Ixekizumab + Adalimumab | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Tocilizumab | Eli Lilly | Phase 3 | 77 |
| adalimumab + Methotrexate | AbbVie | Pre-clinical | 23 |
| Upadacitinib | AbbVie | Phase 1 | 33 |
| Upadacitinib + Tocilizumab | AbbVie | Phase 3 | 77 |
| Adalimumab + Risankizumab | AbbVie | Phase 3 | 77 |
| Adalimumab | AbbVie | Phase 3 | 77 |
| naproxen + esomeprazole | AstraZeneca | Phase 1 | 33 |
| Alendronate (Fosamax) | Merck | Pre-clinical | 23 |
| canakinumab | Novartis | Phase 3 | 77 |
| ACZ885 150 mg (Canakinumab) | Novartis | Phase 3 | 77 |